{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:06:42Z","timestamp":1790856402329,"version":"4.1.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Pancreatic cancer (PC) has poor early diagnosis rates due to its insidious onset. Since human epididymis protein 4 (HE4) is highly expressed in patients with PC, we assessed whether serum HE4 could be a marker for the detection 3 of PC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>Between May 2017 and October 2018, 127 patients with PC were recruited for the study along with 108 healthy controls who underwent health examinations. Serum HE4 concentrations were determined together with levels of carcinoembryonic antigen (CEA) and carbohydrate antigens (CA) 242 (CA242), CA19-9, CA15-3, and CA72-4 by electrochemiluminescence immunoassay (ECLIA) or chemiluminescence immunoassay (CLIA). Correlations between these biomarkers were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Serum levels of all six biomarkers were higher in patients with PC than in controls (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05). No correlation was observed between the serum levels of HE4 and the five other tumor markers, although there were strongly significant positive correlations between CA19-9 and CA15-3, and between CA242 and CA72-4. The lack of correlation indicates that HE4 has independent value in the diagnosis of PC. The combined assessment of serum HE4 levels and the other tumor markers improved the sensitivity of diagnosis. In particular, HE4 combined with CA19-9 performed significantly better than HE4 alone, or CA19-9 combined with the other markers. The HE4\/CA19-9 combination resulted in 94.49% sensitivity and 99.07% specificity (95% confidence interval: 96.9\u2013100).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>HE4 is a biomarker associated with PC with a high specificity, either used alone, or evaluated with other biomarkers together improving the detection of PC. This study may provide a new clinical diagnostic approach for PC detection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijc.ijc_752_19","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T06:28:30Z","timestamp":1712730510000},"page":"223-229","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["A clinical study of serum human epididymis protein 4 (HE4) in the diagnosis of pancreatic cancer"],"prefix":"10.4103","volume":"59","author":[{"given":"Weiqi","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20240828","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)00141-0","article-title":"Pancreatic cancer","volume":"388","author":"Kamisawa","year":"2016","journal-title":"Lancet"},{"key":"R2-10-20240828","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer Statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"R3-10-20240828","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.pan.2018.09.012","article-title":"Diagnosis and management of pancreatic cancer in adults: A summary of guidelines from the UK National Institute for Health and Care Excellence","volume":"18","author":"O'Reilly","year":"2018","journal-title":"Pancreatology"},{"key":"R4-10-20240828","doi-asserted-by":"crossref","first-page":"e555","DOI":"10.1016\/S2214-109X(18)30127-X","article-title":"Changing cancer survival in China during 2003\u201315: A pooled analysis of 17 population-based cancer registries","volume":"6","author":"Zeng","year":"2018","journal-title":"Lancet Global Health"},{"key":"R5-10-20240828","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(08)70337-1","article-title":"New-onset diabetes: A potential clue to the early diagnosis of pancreatic cancer","volume":"10","author":"Pannala","year":"2009","journal-title":"Lancet Oncol"},{"key":"R6-10-20240828","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1155\/2002\/184370","article-title":"Cancer of the pancreas: The best image for early detection--CT, MRI, PET or US?","volume":"16","author":"Hanbidge","year":"2002","journal-title":"Can J Gastroenterol"},{"key":"R7-10-20240828","first-page":"11683","article-title":"Tumor markers CA19-9, CA242 and CEA in the diagnosis of pancreatic cancer: A meta-analysis","volume":"8","author":"Zhang","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"R8-10-20240828","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10238-013-0234-9","article-title":"CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: A meta-analysis","volume":"14","author":"Gui","year":"2014","journal-title":"Clin Exp Med"},{"key":"R9-10-20240828","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/ijc.26422","article-title":"Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer","volume":"131","author":"Liu","year":"2012","journal-title":"Int J Cancer"},{"key":"R10-10-20240828","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.18632\/oncotarget.6819","article-title":"Serum CA125 is a novel predictive marker for pancreatic cancer metastasis and correlates with the metastasis-associated burden","volume":"7","author":"Liu","year":"2016","journal-title":"Oncotarget"},{"key":"R11-10-20240828","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.canlet.2016.10.046","article-title":"CA19-9-Low&Lewis (+) pancreatic cancer: A unique subtype","volume":"385","author":"Luo","year":"2017","journal-title":"Cancer Lett"},{"key":"R12-10-20240828","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ejso.2006.10.004","article-title":"Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer","volume":"33","author":"Goonetilleke","year":"2007","journal-title":"Eur J Surg Oncol"},{"key":"R13-10-20240828","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3349\/ymj.2013.54.3.643","article-title":"Serum CA 19-9 and CEA levels as a prognostic factor in pancreatic adenocarcinoma","volume":"54","author":"Lee","year":"2013","journal-title":"Yonsei Med J"},{"key":"R14-10-20240828","first-page":"15112","article-title":"CA724 is a novel factor for predicting the unresectability in pancreatic adenocarcinoma","volume":"8","author":"Liu","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"R15-10-20240828","doi-asserted-by":"crossref","first-page":"7821574","DOI":"10.1155\/2018\/7821574","article-title":"Assessment of diagnostic values among CA-125, RMI, HE4, and ROMA for cancer prediction in women with nonfunctional ovarian cysts","volume":"2018","author":"Oranratanaphan","year":"2018","journal-title":"Obstet Gynecol Int"},{"key":"R16-10-20240828","doi-asserted-by":"crossref","first-page":"viii6","DOI":"10.1093\/annonc\/mdr472","article-title":"Designing early detection programs for ovarian cancer","volume":"22","author":"Urban","year":"2011","journal-title":"Ann Oncol"},{"key":"R17-10-20240828","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s13277-012-0381-8","article-title":"Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer","volume":"33","author":"Granato","year":"2012","journal-title":"Tumour Biol"},{"key":"R18-10-20240828","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.5588\/ijtld.13.0058","article-title":"Evaluating the clinical significance of serum HE4 levels in lung cancer and pulmonary tuberculosis","volume":"17","author":"Liu","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"key":"R19-10-20240828","doi-asserted-by":"crossref","first-page":"6847","DOI":"10.1007\/s13277-014-1943-8","article-title":"Evaluating the expression and diagnostic value of human epididymis protein 4 (HE4) in small cell lung cancer","volume":"35","author":"Wang","year":"2014","journal-title":"Tumour Biol"},{"key":"R20-10-20240828","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.7754\/Clin.Lab.2018.180222","article-title":"Serum human epididymis secretory protein 4 (HE4) is a potential prognostic biomarker in non-small cell lung cancer","volume":"64","author":"Mo","year":"2018","journal-title":"Clin Lab"},{"key":"R21-10-20240828","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.humpath.2012.07.017","article-title":"Human epididymis protein 4 is up-regulated in gastric and pancreatic adenocarcinomas","volume":"44","author":"O'Neal","year":"2013","journal-title":"Hum Pathol"},{"key":"R22-10-20240828","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/modpathol.3800612","article-title":"Comprehensive analysis of HE4 expression in normal and malignant human tissues","volume":"19","author":"Galgano","year":"2006","journal-title":"Mod Pathol"},{"key":"R23-10-20240828","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1371\/journal.pmed.0050123","article-title":"A mouse to human search for plasma proteome changes associated with pancreatic tumor development","volume":"5","author":"Faca","year":"2008","journal-title":"PLoS Med"},{"key":"R24-10-20240828","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","article-title":"The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM","volume":"17","author":"Edge","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"R25-10-20240828","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/S0016-5085(03)00272-5","article-title":"Risk factors for the development of pancreatic cancer in familial pancreatic cancer kindreds","volume":"124","author":"Rulyak","year":"2003","journal-title":"Gastroenterology"},{"key":"R26-10-20240828","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00432-010-0965-x","article-title":"Serum biomarkers for improved diagnostic of pancreatic cancer: A current overview","volume":"137","author":"Bunger","year":"2011","journal-title":"J Cancer Res Clin Oncol"},{"key":"R27-10-20240828","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/MPA.0b013e3182a6867e","article-title":"Potential prognostic biomarkers of pancreatic cancer","volume":"43","author":"Chen","year":"2014","journal-title":"Pancreas"},{"key":"R28-10-20240828","doi-asserted-by":"crossref","first-page":"9592","DOI":"10.18632\/oncotarget.3562","article-title":"Elevated serum CA72-4 levels predict poor prognosis in pancreatic adenocarcinoma after intensity-modulated radiation therapy","volume":"6","author":"Liu","year":"2015","journal-title":"Oncotarget"},{"key":"R29-10-20240828","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ejso.2004.09.007","article-title":"The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer","volume":"31","author":"Ni","year":"2005","journal-title":"Eur J Surg Oncol"},{"key":"R30-10-20240828","first-page":"340","article-title":"The clinical utility of CA 19-9 in pancreatic adenocarcinoma: Diagnostic and prognostic updates","volume":"13","author":"Poruk","year":"2013","journal-title":"Curr Mol Med"},{"key":"R31-10-20240828","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.3390\/ijms16022956","article-title":"Expression and diagnostic value of HE4 in pancreatic adenocarcinoma","volume":"16","author":"Huang","year":"2015","journal-title":"Int J Mol Sci"},{"key":"R32-10-20240828","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1159\/000442288","article-title":"CA125 and HE4: Measurement tools for ovarian cancer","volume":"81","author":"Zhao","year":"2016","journal-title":"Gynecol Obstet Invest"}],"container-title":["Indian Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.IJC_752_19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:31:28Z","timestamp":1787769088000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.IJC_752_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijc.ijc_752_19","relation":{},"ISSN":["0019-509X"],"issn-type":[{"value":"0019-509X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]}}}